News
Merck, HPV vaccine
Digest more
There’s reason to remain bullish about Merck’s growth prospects in the long run. And at a discounted price, the stock could ...
Merck has received approval from the Food and Drug Administration to expand use of its blockbuster drug, Keytruda, to treat ...
Merck & Co. said it won US approval for a shot that protects against RSV, the most common cause of hospitalization among ...
Merck's Keytruda receives FDA approval for head and neck cancer after showing improved event-free survival in Phase 3 KEYNOTE ...
Merck & Co.’s ambition to get the first oral PCSK9 inhibitor to market came one step closer this morning as the pharma ...
The simplicity of Merck's monoclonal antibody for RSV in infants could be a plus in its competition with AstraZeneca's existing treatment.
Explore more
Known as Enflonsia, the drug will compete for market share with Sanofi and AstraZeneca’s in-demand Beyfortus, which quickly ...
Merck Manuals, a comprehensive digital health resource, announced today it has launched a new search tool enhanced by artificial intelligence to provide patients and other health care consumers with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results